Nintedanib

Global Idiopathic Pulmonary Fibrosis (IPF) Market Analysis Report 2023-2029: Enhancing R&D Operations for Development of Novel Treatments and Improving Access to Treatment - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 14, 2023
Pharmaceutical, Health, Other Health, Prevalence, Market, Just Dance 2023 Edition, Porter's five forces analysis, Route of administration, Idiopathic pulmonary fibrosis, SWOT, IPF, Growth, Administration, Country, Pharmacy, Risk management, Nintedanib, Pirfenidone

The global market for idiopathic pulmonary fibrosis (IPF) is experiencing significant growth.

Key Points: 
  • The global market for idiopathic pulmonary fibrosis (IPF) is experiencing significant growth.
  • This recent market analysis report provides valuable insights into the IPF market, including historical data, current trends, and future projections.
  • The report thoroughly analyzes the IPF market based on its value in USD million.
  • As the prevalence of idiopathic pulmonary fibrosis continues to rise, this market analysis report serves as a valuable resource for healthcare professionals, researchers, and industry stakeholders.

LAMEA Idiopathic Pulmonary Fibrosis Market Report 2022: Increased Use of Branded Drugs Pirfenidone & Nintedanib Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, July 29, 2022
Health, Pharmaceutical, Online, Pulmonary fibrosis, IPF, Industry, Smoking, Hospital, Ageing, Health, Smoke, CAGR, Country, Distribution, Idiopathic pulmonary fibrosis, Lists of countries and territories, Nintedanib, WHO, Prevalence, Pharmaceutical industry, Healthcare, Pirfenidone

The "LAMEA Idiopathic Pulmonary Fibrosis Market Size, Share & Industry Trends Analysis Report By Drug Type, By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Providers, By Country and Growth Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "LAMEA Idiopathic Pulmonary Fibrosis Market Size, Share & Industry Trends Analysis Report By Drug Type, By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Providers, By Country and Growth Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering.
  • The Latin America, Middle East and Africa Idiopathic Pulmonary Fibrosis Market is expected to witness market growth of 12.3% CAGR during the forecast period.
  • Increased use of the costly Pirfenidone (Esbriet) and Nintedanib (Ofev) brands in favor of off-label pharmacological therapy and non-pharmacological treatments has been the key driver for the industry.
  • However, high cost for the treatment of idiopathic pulmonary fibrosis is expected to discourage many people in the region to pursue healthcare goals.

aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod (ATYR1923) for Treatment of Systemic Sclerosis

Retrieved on: 
Wednesday, April 13, 2022
CEO, Neuropilin, Macrophage, Idiopathic pulmonary fibrosis, Fibrosis, Inflammation, COVID-19, Nintedanib, U.S. Securities and Exchange Commission, Pathology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sarcoidosis, Security (finance), Research, Interstitial lung disease, Toxicity, Annual report, Food, Private Securities Litigation Reform Act, Degenerative disease, GLOBE, Death, ATyr Pharma, Patient, FC, Cell, Biomarker, Systemic scleroderma, Lung, Autoimmune disease, SAN, Skin, RNA transfection, LIFE, SEC, NRP2, Forward-looking statement, Safety, Biology, Disorder, Scar, FDA, Scleroderma, Disease, Risk, ILD, Pirfenidone, Pharmaceutical industry

Efzofitimod is a potential first-in-class immunomodulator that downregulates innate and adaptive immune responses in uncontrolled inflammatory disease states via selective modulation of neuropilin-2 (NRP2).

Key Points: 
  • Efzofitimod is a potential first-in-class immunomodulator that downregulates innate and adaptive immune responses in uncontrolled inflammatory disease states via selective modulation of neuropilin-2 (NRP2).
  • Clinical proof-of-concept was recently established for efzofitimod in a Phase 1b/2a study in patients with pulmonary sarcoidosis, a major form of interstitial lung disease (ILD).
  • We are very pleased to receive orphan drug designation for efzofitimod for SSc, which marks the second such designation for our efzofitimod clinical program, said Sanjay S. Shukla, M.D., M.S., President and CEO of aTyr.
  • Orphan drug designation provides certain benefits, including the potential for seven years of market exclusivity following regulatory approval, exemption from FDA application fees and tax credits for qualified clinical trials.

Global Idiopathic Pulmonary Fibrosis (IPF) Markets, 2017-2030 - Insights on Esbriet, Ofev, Tipelukast, Pamrevlumab, KD025, PRM 151, GKT831, and Other IPF Therapies - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 24, 2022
Biotechnology, Pharmaceutical, Health, Boehringer Ingelheim, ILD, Population, Degenerative disease, Genentech, Type–token distinction, Growth, Scheidler v. National Organization for Women (2006), IPF, PFF, Prevalence, Investment, Organization, Fibrosis, COVID-19, Vicki Belo, NICE, Advantage, SWOT, Nintedanib, Interstitial lung disease, Competitive landscape, Adult, Research report, USD, Idiopathic pulmonary fibrosis, Safety, FDA, U.S. FDA, Phenotype, Lung cancer, Patient, R, National Institute for Health and Care Excellence, Technology, CAGR, Association, National Institute, Aluminium, Renewable energy, Pharmaceutical industry, Retail, Fine chemical, Pirfenidone

Based on region, the Global Idiopathic Pulmonary Fibrosis (IPF) market is divided into the U.S., EU5, and Japan.

Key Points: 
  • Based on region, the Global Idiopathic Pulmonary Fibrosis (IPF) market is divided into the U.S., EU5, and Japan.
  • What are the inhibiting factors and impact of COVID-19 on the Global Idiopathic Pulmonary Fibrosis (IPF) Market during the assessment period?
  • Which are the products/segments/applications/areas to invest in over the assessment period in the Global Idiopathic Pulmonary Fibrosis (IPF) Market?
  • What modes and strategic moves are considered favorable for entering the Global Idiopathic Pulmonary Fibrosis (IPF) Market?

Global Idiopathic Pulmonary Fibrosis (IPF) Market Insights, Pipeline and Forecast Report 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 17, 2022
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Research, Patient, R, AbbVie, COVID-19, Growth, Gilead Sciences, Disease, Pulmonary fibrosis, Merck Group, Galapagos NV, Bristol Myers Squibb, Boehringer Ingelheim, Health, Cipla, Liminal BioSciences, USD, IPF, Prevalence, Nintedanib, Lithium, Pharmaceutical industry, Pirfenidone

The "Global Idiopathic Pulmonary Fibrosis (IPF) Market - Analysis By Drug Type, End User, By Region, By Country (2021 Edition): Market Insights, Pipeline and Forecast with Impact of COVID-19 (2021-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Idiopathic Pulmonary Fibrosis (IPF) Market - Analysis By Drug Type, End User, By Region, By Country (2021 Edition): Market Insights, Pipeline and Forecast with Impact of COVID-19 (2021-2026)" report has been added to ResearchAndMarkets.com's offering.
  • Global Idiopathic Pulmonary Fibrosis Market is projected to display robust growth valued at USD 3271.3 Million in the year 2020 with North America leading the regional market share.
  • The major factors that drive the growth of the global idiopathic pulmonary fibrosis market include rise in prevalence of fibrotic disease and increase in geriatric population.
  • Furthermore, changing lifestyle patterns and increasing consumption of nicotine products is providing a thrust to the market growth.

Global Interstitial Lung Disease Market (2021 to 2028) - Size, Share, Outlook and Opportunity Analysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 29, 2021
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Idiopathic pulmonary fibrosis, Marketing, Growth, Degenerative disease, IPF, Decision-making, Nintedanib, CAGR, US, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Industry, FDA, Pirfenidone

Increasing number of drug approvals from regulatory bodies is expected to drive the growth of global interstitial lung disease market during the forecast period.

Key Points: 
  • Increasing number of drug approvals from regulatory bodies is expected to drive the growth of global interstitial lung disease market during the forecast period.
  • For instance, in October 2014, the U.S. Food and Drug Administration (FDA) approved pirfenidone (Esbriet) and nintedanib (Ofev) for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease that makes breathing difficult and causes irreversible lung damage.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
    The global interstitial lung disease market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
    Stakeholders would have ease in decision making through various strategy matrices used in analyzing the interstitial lung disease market.
  • Global Interstitial Lung Disease Market, By Disease Type:

Interstitial Lung Disease Curriculum Supports Healthcare Providers and Patients

Retrieved on: 
Tuesday, June 8, 2021
Lung disorders, Medicine, Clinical medicine, Health, Interstitial lung disease, Idiopathic pulmonary fibrosis, Pulmonary fibrosis, Fibrosis, IPF, Nintedanib, Idiopathic interstitial pneumonia

The curriculum features material on idiopathic pulmonary fibrosis (IPF), progressive fibrosing interstitial lung disease (PF-ILD), and systemic sclerosis ILD (SSc-ILD).Interstitial lung disease affects more than 200,000 people in the US and can lead to scarring (fibrosis) of the lungs and long-term health implications.

Key Points: 
  • The curriculum features material on idiopathic pulmonary fibrosis (IPF), progressive fibrosing interstitial lung disease (PF-ILD), and systemic sclerosis ILD (SSc-ILD).Interstitial lung disease affects more than 200,000 people in the US and can lead to scarring (fibrosis) of the lungs and long-term health implications.
  • "We are pleased to partner with Paradigm to develop educational programs for providers caring for patients with ILD," said William T. Schmidt, President and Chief Executive Officer of the PFF.
  • "This content is crucial in ensuring that knowledge of how to diagnose and treat patients with these complex conditions is accessible to providers nationwide."
  • Paradigm's missionis to provide educational initiatives designed to bridge identified professional practice gaps of physicians and other healthcare providers.

Global Idiopathic Pulmonary Fibrosis Industry to 2029 - Opportunity Analysis and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, May 7, 2021
Health, Pharmaceutical, Lung disorders, Health sciences, Health, Breakthrough therapy, Orphan drugs, Pneumonia, Idiopathic pulmonary fibrosis, Interstitial lung disease, Idiopathic interstitial pneumonia, Pulmonary fibrosis, Nintedanib, Boehringer Ingelheim

b'The "Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecasts to 2029 (Event Driven Update)" report has been added to ResearchAndMarkets.com\'s offering.\nIdiopathic pulmonary fibrosis (IPF) is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs).

Key Points: 
  • b'The "Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecasts to 2029 (Event Driven Update)" report has been added to ResearchAndMarkets.com\'s offering.\nIdiopathic pulmonary fibrosis (IPF) is the most common subtype of idiopathic interstitial pneumonias (IIPs), which belong to a group of rare diseases termed interstitial lung diseases (ILDs).
  • Idiopathic pulmonary fibrosis (IPF) is a new and rapidly-establishing market, which, before 2011 was non-existent, with no approved pharmaceutical treatments for the chronic, debilitating disease, which has an abysmal prognosis.
  • However, the last decade has seen a period of explosive growth in the IPF market following the entry of two pharmacological small molecule treatments; Roche\'s Esbriet and Boehringer Ingelheim\'s Ofev.
  • Insightful review of the key industry drivers, restraints and challenges.

InspirMed to Present at the 23rd International Society for Aerosols in Medicine (ISAM) Congress

Retrieved on: 
Monday, April 26, 2021
Health sciences, Drugs, Health care, Orphan drugs, Tyrosine kinase inhibitors, Respiratory therapy, Primary alcohols, GS-441524, Bioavailability, Nebulizer, Nintedanib, Hydroxychloroquine

The objective of the Congress is to foster scientific discussions around the current state-of-the-art for aerosols in medicine.\nTLC previously presented an inhalable liposomal nintedanib for enhanced treatment of pulmonary diseases at the 22nd ISAM Congress in Switzerland.

Key Points: 
  • The objective of the Congress is to foster scientific discussions around the current state-of-the-art for aerosols in medicine.\nTLC previously presented an inhalable liposomal nintedanib for enhanced treatment of pulmonary diseases at the 22nd ISAM Congress in Switzerland.
  • However, the low oral bioavailability of GS-441524 means an extremely high oral dose would be required to achieve therapeutic levels.
  • HCQ has shown potential in prophylaxis and/or treatment for COVID-19 in in vitro and preliminary clinical trial studies, but orally administered HCQ cannot reach therapeutic levels due to its dose-limiting toxicities.
  • ISPM19 is designed to be cost-effective, easily accessible and can be self-administered with a portable nebulizer.

Global Idiopathic Pulmonary Fibrosis Market Trajectory & Analytics Report 2021: Focus on Pirfenidone and Nintedanib - Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 21, 2021
Health, Cardiology, Breakthrough therapy, Orphan drugs, Health sciences, Drugs, Countries, Pirfenidone, Nintedanib, Idiopathic pulmonary fibrosis, Compound annual growth rate, Asia, Pulmonary fibrosis, China

b'World Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR\nWorld Historic Review for Idiopathic Pulmonary Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR\nWorld 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027\nWorld Current & Future Analysis for PIRFENIDONE by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR\nWorld Historic Review for PIRFENIDONE by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR\nWorld 15-Year Perspective for PIRFENIDONE by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027\nWorld Current & Future Analysis for NINTEDANIB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR\nWorld Historic Review for NINTEDANIB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR\nWorld 15-Year Perspective for NINTEDANIB by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210421005474/en/\n'

Key Points: 
  • b'World Current & Future Analysis for Idiopathic Pulmonary Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR\nWorld Historic Review for Idiopathic Pulmonary Fibrosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR\nWorld 15-Year Perspective for Idiopathic Pulmonary Fibrosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027\nWorld Current & Future Analysis for PIRFENIDONE by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR\nWorld Historic Review for PIRFENIDONE by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR\nWorld 15-Year Perspective for PIRFENIDONE by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027\nWorld Current & Future Analysis for NINTEDANIB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR\nWorld Historic Review for NINTEDANIB by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR\nWorld 15-Year Perspective for NINTEDANIB by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210421005474/en/\n'